Overexpression of KRASIM can reduce the level of proto-oncogene KRAS protein, which then inhibits the ERK signaling pathway in HCC cells causing a reduction in the growth and proliferation of HCC cells. This evidence concerns the gene NCBP2AS2 and hepatocellular carcinoma.